Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

被引:12
作者
Lazzaroni, Elisa [1 ,2 ]
Lunati, Maria Elena [1 ]
Montefusco, Laura [1 ]
Pastore, Ida [1 ]
Chebat, Enrica [1 ]
Cimino, Vincenzo [2 ,3 ]
Morpurgo, Paola Silvia [1 ]
Muratori, Milena [1 ]
Plebani, Laura [1 ]
Bolla, Andrea [1 ]
Rossi, Antonio [1 ]
Vallone, Luciana [1 ]
Gandolfi, Alessandra [1 ]
Tinari, Camilla [1 ]
D'Addio, Francesca [1 ,2 ]
Ben Nasr, Moufida [2 ]
Loretelli, Cristian [2 ]
Scaranna, Cristiana [4 ]
Bellante, Rosalia [4 ]
Manfrini, Roberto [5 ,6 ]
Muratori, Fabrizio [7 ]
Franzetti, Ivano [8 ]
Orsi, Emanuela [9 ]
Gazzaruso, Carmine [10 ,11 ]
Ghelardi, Renata [12 ]
Desenzani, Paolo [13 ]
Genovese, Stefano [14 ]
Girelli, Angela [15 ]
Folli, Franco [5 ,6 ]
Berra, Cesare [16 ]
Fiorina, Paolo [1 ,2 ,17 ]
机构
[1] ASST Fatebenefratelli Sacco, Div Endocrinol, Milan, Italy
[2] Univ Milan, Ctr T1D, Pediat Clin Res Ctr Romeo Enr Invernizzi, DIBIC, Milan, Italy
[3] Pio Albergo Trivulzio, Endocrinol & Diabetol, Milan, Italy
[4] ASST Papa Giovanni XXIII, Div Endocrinol & Diabetol, Bergamo, Italy
[5] Univ Milan, Dept Hlth Sci, Endocrinol & Metab, Milan, Italy
[6] San Paolo Hosp, Dept Unit Diabet & Metab, ASST Santi Paolo & Carlo, Milan, Italy
[7] St Anna Hosp ASST Lariana, Div Endocrinol & Diabetol, Como, Italy
[8] S Antonio Abate Hosp, Div Endocrinol & Diabetol, Gallarate, Italy
[9] IRCCS Ca Granda Osped Maggiore Policlin Fdn, Diabet Serv, Endocrinol & Metab Dis Unit, Milan, Italy
[10] Hosp Grp San Donato, Metab & Vasc Dis Unit, Diabet & Endocrine, Clin Inst Beato Matteo, Vigevano, Italy
[11] Hosp Grp San Donato, Ctr Appl Clin Res CeRCA, Clin Inst Beato Matteo, Vigevano, Italy
[12] ASST Melegnano Martesana, Unit Diabetol, San Giuliano Milanese, Italy
[13] ASST Spedali Civili, Unit Diabetol, Brescia, Italy
[14] Ctr Cardiol Monzino IRCCS, I-20138 Milan, Italy
[15] Spedali Civil Brescia, Unit Diabetol, Brescia, Italy
[16] IRCCS Multimed, Dept Endocrinol Nutr & Metab Dis, Milan, Italy
[17] Harvard Med Sch, Boston Childrens Hosp, Div Nephrol, Boston, MA USA
关键词
Dapagliflozin; Hb1Ac; Albuminuria; Cardio-vascular risk; INADEQUATE GLYCEMIC CONTROL; CARDIOVASCULAR OUTCOMES; SGLT2; INHIBITORS; BLOOD-PRESSURE; DOUBLE-BLIND; DISEASE; EMPAGLIFLOZIN; MORTALITY; MUSCLE; RISK;
D O I
10.1016/j.phrs.2022.106374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (-0.6 +/- 1.8%) as well as in BMI (-1.5 +/- 5.2 kg/m(2)). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D.
引用
收藏
页数:6
相关论文
共 50 条
[31]   Dapagliflozin A Review of its Use in Type 2 Diabetes Mellitus [J].
Plosker, Greg L. .
DRUGS, 2012, 72 (17) :2289-2312
[32]   Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin [J].
Avgerinos, Ioannis ;
Liakos, Aris ;
Tsapas, Apostolos ;
Bekiari, Eleni .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 :2549-2557
[33]   Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes [J].
Le, Yunyi ;
Yang, Jin ;
Li, Fei ;
Jiang, Yafei ;
Wei, Tianjiao ;
Wang, Dandan ;
Wang, Kangli ;
Cui, Xiaona ;
Lin, Xiafang ;
Yang, Kun ;
Hong, Tianpei ;
Wei, Rui .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (03)
[34]   Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus [J].
Tang, W. ;
Leil, T. A. ;
Johnsson, E. ;
Boulton, D. W. ;
LaCreta, F. .
DIABETES OBESITY & METABOLISM, 2016, 18 (03) :236-240
[35]   The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats [J].
Rodrigues, Eder Anderson ;
Rosa, Camila Moreno ;
Campos, Dijon Henrique Salome ;
Damatto, Felipe Cesar ;
Murata, Gilson Masahiro ;
Souza, Lidiane Moreira ;
Pagan, Luana Urbano ;
Gatto, Mariana ;
Brosler, Jessica Yumi ;
Souza, Hebreia Oliveira Almeida ;
Martins, Mario Machado ;
Bastos, Luciana Machado ;
Tanni, Suzana Erico ;
Okoshi, Katashi ;
Okoshi, Marina Politi .
DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
[36]   Dapagliflozin for the treatment of type 2 diabetes: a review of the literature [J].
Saeed, Mujahid A. ;
Narendran, Parth .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 :2493-2505
[37]   Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus [J].
Melin, Johanna ;
Tang, Weifeng ;
Rekic, Dinko ;
Hamren, Bengt ;
Penland, Robert C. ;
Boulton, David W. ;
Parkinson, Joanna .
JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (10) :1227-1235
[38]   Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus [J].
Dogruel, Hakan ;
Atlim, Hatice Tuluce ;
Aydemir, Mustafa ;
Yilmaz, Nusret ;
Sari, Ramazan .
IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (05) :2189-2195
[39]   Dapagliflozin for the Treatment of Type 2 Diabetes [J].
Anderson, Sarah L. ;
Marrs, Joel C. .
ANNALS OF PHARMACOTHERAPY, 2012, 46 (04) :590-598
[40]   Dapagliflozin: A Review in Type 2 Diabetes [J].
Dhillon, Sohita .
DRUGS, 2019, 79 (10) :1135-1146